Amends title XIX of the Social Security Act to establish value-based purchasing (VBP) arrangements under the Medicaid program.
Introduces provisions for multiple best price points for drugs under VBP arrangements, ensuring manufacturers offer these arrangements to all states.
Defines average manufacturer price to include refunds or rebates related to patient outcomes under VBP arrangements.
Requires the Secretary of Health and Human Services to implement rulemaking for these amendments within 180 days of enactment.
Provides guidance for state Medicaid agencies on entering VBP arrangements for inpatient drugs, including multi-state agreements for funding transfers.
Modifies the Anti-Kickback Statute to exempt certain remuneration related to VBP arrangements from penalties.
Mandates a study by the Comptroller General on the impact of VBP arrangements on patient access, outcomes, health system costs, and Medicaid expenditures.
Requires a report on the study’s findings to be submitted to Congress by June 30, 2028.
